AIM
AIM ImmunoTech Inc.
Price Chart
Latest Quote
$0.43
-0.01 (-1.71%)
Current Price
| Previous Close | $0.44 |
| Open | $0.43 |
| Day High | $0.46 |
| Day Low | $0.43 |
| Volume | 2,083,551 |
Stock Information
| Shares Outstanding | 26.95M |
| Total Debt | $4.90M |
| Cash Equivalents | $3.05M |
| Revenue | $88K |
| Net Income | $-13.96M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $10.94M |
| EPS (TTM) | $-4.31 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.91M |
| Sales | $88K |
| Income | $-13.96M |
| Book/sh | $-3.19 |
| Cash/sh | $0.11 |
| Employees | 19 |
Financial Ratios
| Quick Ratio | 0.49 |
| Current Ratio | 0.53 |
Returns & Margins
| ROA | -101.32% |
| Gross Margin | -45.46% |
| Operating Margin | -14057.14% |
Ownership
| Insider Ownership | 1.98% |
| Institutional Ownership | 2.48% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.78 |
| PEG | 0.71 |
| P/S | 124.32 |
| P/B | -0.13 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $5.25 |
Technical Indicators
| SMA20 | $0.45 |
| SMA50 | $0.48 |
| SMA200 | $1.30 |
| RSI | 56.30 |
| ATR | 0.1964 |
| Shares Float | 7.99M |
| Short Float | 3.79% |
| Short Ratio | 1.01 |
| Volatility | 1.24 |
| Rel Volume | 0.02 |
Performance History
| Week | -21.15% |
| Month | +51.85% |
| Quarter | -43.84% |
| 6 Months | -70.85% |
| YTD | -64.48% |
| Year | -93.96% |
| 3 Years | -99.08% |
| 5 Years | -99.81% |
| 10 Years | -99.99% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $0.41 | 2,030,500 |
| 2026-06-11 | $0.46 | 3,055,300 |
| 2026-06-10 | $0.44 | 6,097,800 |
| 2026-06-09 | $0.40 | 10,736,600 |
| 2026-06-08 | $0.52 | 68,569,800 |
| 2026-06-05 | $0.52 | 7,691,500 |
| 2026-06-04 | $0.59 | 45,379,000 |
| 2026-06-03 | $0.73 | 8,560,600 |
| 2026-06-02 | $0.83 | 25,336,700 |
| 2026-06-01 | $0.90 | 359,966,000 |
| 2026-05-29 | $0.41 | 12,135,200 |
| 2026-05-28 | $0.44 | 85,991,800 |
| 2026-05-27 | $0.40 | 496,390,700 |
| 2026-05-26 | $0.23 | 5,770,700 |
| 2026-05-22 | $0.24 | 3,823,600 |
| 2026-05-21 | $0.24 | 6,752,000 |
| 2026-05-20 | $0.25 | 13,252,300 |
| 2026-05-19 | $0.41 | 13,098,900 |
| 2026-05-18 | $0.41 | 471,583,400 |
| 2026-05-15 | $0.25 | 721,000 |
| 2026-05-14 | $0.26 | 1,043,900 |
| 2026-05-13 | $0.27 | 699,000 |
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
đ° Latest News
AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early â CEO Sees 'Value-Inflection Period' Ahead
Stocktwits âĸ 2026-06-01T14:19:22Z
Transcript: Aimia Q1 2026 Earnings Conference Call
Benzinga âĸ 2026-05-13T13:47:40Z
We Might See A Profit From Aimia Inc. (TSE:AIM) Soon
Simply Wall St. âĸ 2026-03-26T12:51:11Z
Aimia Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-24T15:36:49Z
Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial
Insider Monkey âĸ 2026-03-24T14:43:06Z
Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year?
Zacks âĸ 2026-01-28T14:40:02Z
AIM ImmunoTech Files Preliminary Prospectus for Rights Offering
MT Newswires âĸ 2026-01-23T18:44:50ZIs AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2026-01-08T14:40:02Z
Zacks.com featured highlights include The Honest Company, Dutch, AIM ImmunoTech, Masimo and Cognizant Technology Solutions
Zacks âĸ 2025-10-23T12:51:00Z
Bet On 5 Top-Ranked Stocks With Rising P/E
Zacks âĸ 2025-10-22T16:02:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $128,000 | $31,000 | $42,000 | $0 |
| Cost Of Revenue | $128,000 | $31,000 | $42,000 | $0 |
| Total Revenue | $88,000 | $170,000 | $202,000 | $141,000 |
| Operating Revenue | $88,000 | $170,000 | $202,000 | $141,000 |
| Expenses | ||||
| Interest Expense | $812,000 | $585,000 | $0 | $0 |
| Total Expenses | $11,752,000 | $19,942,000 | $32,118,000 | $20,064,000 |
| Other Income Expense | $-4,665,000 | $-2,155,000 | $1,885,000 | $-151,000 |
| Other Non Operating Income Expenses | $-4,410,000 | $-1,604,000 | $1,667,000 | $1,490,000 |
| Net Non Operating Interest Income Expense | $2,371,000 | $4,607,000 | $1,069,000 | $629,000 |
| Interest Expense Non Operating | $812,000 | $585,000 | $0 | $0 |
| Operating Expense | $11,624,000 | $19,911,000 | $32,076,000 | $20,064,000 |
| General And Administrative Expense | $7,700,000 | $13,714,000 | $21,137,000 | $13,074,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-13,958,000 | $-17,320,000 | $-28,962,000 | $-19,445,000 |
| Net Interest Income | $2,371,000 | $4,607,000 | $1,069,000 | $629,000 |
| Interest Income | $3,183,000 | $5,192,000 | $1,069,000 | $629,000 |
| Normalized Income | $-13,703,000 | $-16,769,000 | $-29,180,000 | $-17,804,000 |
| Net Income From Continuing And Discontinued Operation | $-13,958,000 | $-17,320,000 | $-28,962,000 | $-19,445,000 |
| Total Operating Income As Reported | $-11,664,000 | $-19,772,000 | $-31,916,000 | $-19,923,000 |
| Net Income Common Stockholders | $-13,958,000 | $-17,320,000 | $-28,962,000 | $-19,445,000 |
| Net Income | $-13,958,000 | $-17,320,000 | $-28,962,000 | $-19,445,000 |
| Net Income Including Noncontrolling Interests | $-13,958,000 | $-17,320,000 | $-28,962,000 | $-19,445,000 |
| Net Income Continuous Operations | $-13,958,000 | $-17,320,000 | $-28,962,000 | $-19,445,000 |
| Pretax Income | $-13,958,000 | $-17,320,000 | $-28,962,000 | $-19,445,000 |
| Interest Income Non Operating | $3,183,000 | $5,192,000 | $1,069,000 | $629,000 |
| Operating Income | $-11,664,000 | $-19,772,000 | $-31,916,000 | $-19,923,000 |
| Gross Profit | $-40,000 | $139,000 | $160,000 | $141,000 |
| Special Income Charges | - | $0 | $18,000 | $3,000 |
| Per Share | ||||
| Diluted EPS | $-8.62 | $-30.92 | $-59.94 | $-39.96 |
| Basic EPS | $-8.62 | $-30.92 | $-59.94 | $-39.96 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-12,681,000 | $-15,938,000 | $-28,942,000 | $-18,026,000 |
| Total Unusual Items | $-255,000 | $-551,000 | $218,000 | $-1,641,000 |
| Total Unusual Items Excluding Goodwill | $-255,000 | $-551,000 | $218,000 | $-1,641,000 |
| Reconciled Depreciation | $210,000 | $246,000 | $238,000 | $256,000 |
| EBITDA (Bullshit earnings) | $-12,936,000 | $-16,489,000 | $-28,724,000 | $-19,667,000 |
| EBIT | $-13,146,000 | $-16,735,000 | $-28,962,000 | $-19,923,000 |
| Diluted Average Shares | $1,618,617 | $560,168 | $486,339 | $480,953 |
| Basic Average Shares | $1,618,617 | $560,168 | $486,339 | $480,953 |
| Diluted NI Availto Com Stockholders | $-13,958,000 | $-17,320,000 | $-28,962,000 | $-19,445,000 |
| Gain On Sale Of Security | $-255,000 | $-551,000 | $200,000 | $-1,644,000 |
| Research And Development | $3,924,000 | $6,197,000 | $10,939,000 | $6,990,000 |
| Selling General And Administration | $7,700,000 | $13,714,000 | $21,137,000 | $13,074,000 |
| Other Gand A | $7,700,000 | $13,714,000 | $21,137,000 | $13,074,000 |
| Gain On Sale Of Ppe | - | $0 | $18,000 | $3,000 |
| Write Off | - | - | - | $0 |
| Other Special Charges | - | - | - | - |
| Impairment Of Capital Assets | - | - | - | - |
Fetched: 2026-06-08
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-11,444,000 | $-3,916,000 | $7,921,000 | $36,527,000 |
| Total Assets | $5,782,000 | $8,608,000 | $19,381,000 | $40,488,000 |
| Total Non Current Assets | $2,487,000 | $4,432,000 | $4,825,000 | $4,167,000 |
| Other Non Current Assets | $377,000 | $1,112,000 | $1,688,000 | $1,202,000 |
| Goodwill And Other Intangible Assets | $1,661,000 | $2,594,000 | $2,313,000 | $1,941,000 |
| Other Intangible Assets | $1,661,000 | $2,594,000 | $2,313,000 | $1,941,000 |
| Current Assets | $3,295,000 | $4,176,000 | $14,556,000 | $36,321,000 |
| Other Current Assets | $241,000 | $199,000 | $302,000 | $455,000 |
| Receivables | $7,000 | $0 | $1,184,000 | $1,676,000 |
| Other Receivables | $7,000 | - | $1,184,000 | $1,676,000 |
| Cash Cash Equivalents And Short Term Investments | $3,047,000 | $3,977,000 | $13,070,000 | $34,190,000 |
| Cash And Cash Equivalents | $2,985,000 | $1,701,000 | $5,439,000 | $27,053,000 |
| Accounts Receivable | - | - | - | $1,676,000 |
| Investmentin Financial Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $1,491,000 | $606,000 | - | - |
| Total Debt | $4,896,000 | $2,941,000 | $718,000 | $837,000 |
| Long Term Debt And Capital Lease Obligation | $1,097,000 | $395,000 | $495,000 | $659,000 |
| Long Term Debt | $927,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $3,799,000 | $2,546,000 | $223,000 | $178,000 |
| Current Debt | $3,549,000 | $2,307,000 | - | - |
| Other Current Borrowings | $3,549,000 | $2,307,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $15,565,000 | $9,930,000 | $9,147,000 | $2,020,000 |
| Total Non Current Liabilities Net Minority Interest | $9,341,000 | $395,000 | $495,000 | $659,000 |
| Derivative Product Liabilities | $8,244,000 | $0 | - | $0 |
| Current Liabilities | $6,224,000 | $9,535,000 | $8,652,000 | $1,361,000 |
| Payables And Accrued Expenses | $2,207,000 | $6,988,000 | $8,015,000 | $1,182,000 |
| Interest Payable | $64,000 | $11,000 | $0 | - |
| Payables | $1,630,000 | $6,383,000 | $6,443,000 | $377,000 |
| Accounts Payable | $1,630,000 | $6,383,000 | $6,443,000 | $377,000 |
| Current Notes Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $-9,783,000 | $-1,322,000 | $9,545,000 | $37,772,000 |
| Total Equity Gross Minority Interest | $-9,783,000 | $-1,322,000 | $10,234,000 | $38,468,000 |
| Stockholders Equity | $-9,783,000 | $-1,322,000 | $10,234,000 | $38,468,000 |
| Retained Earnings | $-440,786,000 | $-426,828,000 | $-409,508,000 | $-380,546,000 |
| Preferred Stock Equity | - | - | $689,000 | $696,000 |
| Gains Losses Not Affecting Retained Earnings | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $3,072,944 | $655,918 | $491,515 | $481,323 |
| Share Issued | $3,072,944 | $655,918 | $491,515 | $481,323 |
| Tangible Book Value | $-11,444,000 | $-3,916,000 | $7,232,000 | $35,831,000 |
| Invested Capital | $-5,307,000 | $985,000 | $9,545,000 | $37,772,000 |
| Working Capital | $-2,929,000 | $-5,359,000 | $5,904,000 | $34,960,000 |
| Capital Lease Obligations | $420,000 | $634,000 | $718,000 | $837,000 |
| Total Capitalization | $-8,856,000 | $-1,322,000 | $10,234,000 | $38,468,000 |
| Additional Paid In Capital | $431,000,000 | $425,505,000 | $419,004,000 | $418,270,000 |
| Capital Stock | $3,000 | $1,000 | $738,000 | $744,000 |
| Common Stock | $3,000 | $1,000 | $49,000 | $48,000 |
| Preferred Stock | $0 | $0 | $689,000 | $696,000 |
| Long Term Capital Lease Obligation | $170,000 | $395,000 | $495,000 | $659,000 |
| Current Capital Lease Obligation | $250,000 | $239,000 | $223,000 | $178,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $218,000 | $1,000 | $414,000 | $1,000 |
| Current Accrued Expenses | $577,000 | $605,000 | $1,572,000 | $805,000 |
| Net PPE | $449,000 | $726,000 | $824,000 | $1,024,000 |
| Accumulated Depreciation | $-1,395,000 | $-1,358,000 | $-1,321,000 | $-2,038,000 |
| Gross PPE | $1,844,000 | $2,084,000 | $2,145,000 | $3,062,000 |
| Other Properties | $378,000 | $618,000 | $697,000 | $829,000 |
| Machinery Furniture Equipment | $1,466,000 | $1,466,000 | $1,448,000 | $2,233,000 |
| Other Short Term Investments | $62,000 | $2,276,000 | $7,631,000 | $7,137,000 |
| Properties | - | - | - | $0 |
| Investments And Advances | - | - | - | - |
Fetched: 2026-06-08
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-11,335,000 | $-15,444,000 | $-21,852,000 | $-16,379,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-10,957,000 | $-14,888,000 | $-21,267,000 | $-16,108,000 |
| Cash Flow From Continuing Operating Activities | $-10,957,000 | $-14,888,000 | $-21,267,000 | $-16,108,000 |
| Operating Gains Losses | $4,666,000 | $551,000 | $-218,000 | $1,644,000 |
| Investing Activities | ||||
| Capital Expenditure | $-378,000 | $-556,000 | $-585,000 | $-271,000 |
| Investing Cash Flow | $1,853,000 | $4,706,000 | $-832,000 | $10,988,000 |
| Cash Flow From Continuing Investing Activities | $1,853,000 | $4,706,000 | $-832,000 | $10,988,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $8,298,000 | $892,000 | $485,000 | $80,000 |
| Financing Cash Flow | $10,388,000 | $6,444,000 | $485,000 | $80,000 |
| Cash Flow From Continuing Financing Activities | $10,388,000 | $6,444,000 | $485,000 | $80,000 |
| Net Common Stock Issuance | $8,298,000 | $892,000 | $485,000 | $80,000 |
| Common Stock Issuance | $8,298,000 | $892,000 | $485,000 | $80,000 |
| Other | ||||
| Repayment Of Debt | $-660,000 | $-251,000 | $0 | $0 |
| Issuance Of Debt | $2,750,000 | $2,500,000 | $0 | - |
| End Cash Position | $2,985,000 | $1,701,000 | $5,439,000 | $27,053,000 |
| Beginning Cash Position | $1,701,000 | $5,439,000 | $27,053,000 | $32,093,000 |
| Changes In Cash | $1,284,000 | $-3,738,000 | $-21,614,000 | $-5,040,000 |
| Proceeds From Stock Option Exercised | $0 | $3,303,000 | $0 | - |
| Net Issuance Payments Of Debt | $2,090,000 | $2,249,000 | $0 | $0 |
| Net Long Term Debt Issuance | $2,090,000 | $2,249,000 | $0 | $0 |
| Long Term Debt Payments | $-660,000 | $-251,000 | $0 | $0 |
| Long Term Debt Issuance | $2,750,000 | $2,500,000 | $0 | - |
| Net Investment Purchase And Sale | $2,231,000 | $5,262,000 | $-294,000 | $7,359,000 |
| Sale Of Investment | $2,322,000 | $5,623,000 | $1,299,000 | $10,083,000 |
| Purchase Of Investment | $-91,000 | $-361,000 | $-1,593,000 | $-2,724,000 |
| Net Intangibles Purchase And Sale | $-378,000 | $-538,000 | $-585,000 | $-185,000 |
| Purchase Of Intangibles | $-378,000 | $-538,000 | $-585,000 | $-185,000 |
| Net PPE Purchase And Sale | $0 | $-18,000 | $47,000 | $3,814,000 |
| Purchase Of PPE | $0 | $-18,000 | $0 | $-86,000 |
| Change In Working Capital | $-878,000 | $296,000 | $7,131,000 | $966,000 |
| Change In Other Current Liabilities | $-268,000 | $-309,000 | $-274,000 | $688,000 |
| Change In Other Current Assets | $735,000 | $576,000 | $-486,000 | $-83,000 |
| Change In Payables And Accrued Expense | $-1,296,000 | $-1,258,000 | $7,246,000 | $547,000 |
| Change In Accrued Expense | $416,000 | $-1,198,000 | $1,180,000 | $368,000 |
| Change In Payable | $-1,712,000 | $-60,000 | $6,066,000 | $179,000 |
| Change In Account Payable | $-1,712,000 | $-60,000 | $6,066,000 | $179,000 |
| Change In Prepaid Assets | $-42,000 | $103,000 | $153,000 | $-151,000 |
| Change In Receivables | $-7,000 | $1,184,000 | $492,000 | $-35,000 |
| Other Non Cash Items | $-2,195,000 | $605,000 | $287,000 | $-680,000 |
| Stock Based Compensation | $60,000 | $686,000 | $243,000 | $954,000 |
| Asset Impairment Charge | $1,138,000 | $48,000 | $14,000 | $0 |
| Depreciation Amortization Depletion | $210,000 | $246,000 | $238,000 | $256,000 |
| Depreciation And Amortization | $210,000 | $246,000 | $238,000 | $256,000 |
| Amortization Cash Flow | $173,000 | $209,000 | $199,000 | $218,000 |
| Amortization Of Intangibles | $173,000 | $209,000 | $199,000 | $218,000 |
| Depreciation | $37,000 | $37,000 | $39,000 | $38,000 |
| Gain Loss On Investment Securities | $4,666,000 | $551,000 | $-200,000 | $1,644,000 |
| Net Income From Continuing Operations | $-13,958,000 | $-17,320,000 | $-28,962,000 | $-19,445,000 |
| Sale Of PPE | - | $0 | $47,000 | $3,900,000 |
| Gain Loss On Sale Of PPE | - | $0 | $-18,000 | $0 |
| Deferred Tax | - | - | $0 | $197,000 |
| Deferred Income Tax | - | - | $0 | $197,000 |
| Changes In Account Receivables | - | - | - | $0 |
| Change In Interest Payable | - | - | - | - |
| Provisionand Write Offof Assets | - | - | - | - |
Fetched: 2026-06-08